Ereshefsky L, Riesenman C, Lam Y W
Clinical Pharmacy Programs, University of Texas Health Science Center, San Antonio State Hospital, USA.
J Clin Psychiatry. 1996;57 Suppl 8:17-24; discussion 25.
The article focuses on the effects of the serotonin selective reuptake inhibitors (SSRIs) on specific drug metabolizing isoenzymes: CYP2D6, CYP3A3/4, CYP1A2, CYP2C9, and CYP2C19. Both in vitro and in vivo data regarding the inhibition potential of the SSRIs at each of these isoenzyme systems are reviewed. In general, the magnitude of the in vivo interactions between the SSRIs and substrates for these isoenzyme systems mirrors to a large extent their in vitro inhibitory potencies. However, in vitro work is limited owing to pharmacokinetic considerations, the effect of metabolites on the isoenzymes, and the likelihood that several isoenzymes are co-responsible for the metabolism of a substrate.
本文重点关注5-羟色胺选择性再摄取抑制剂（SSRI）对特定药物代谢同工酶的影响：细胞色素P450 2D6（CYP2D6）、细胞色素P450 3A3/4（CYP3A3/4）、细胞色素P450 1A2（CYP1A2）、细胞色素P450 2C9（CYP2C9）和细胞色素P450 2C19（CYP2C19）。本文综述了关于SSRI在这些同工酶系统中每个系统的抑制潜力的体外和体内数据。一般来说，SSRI与这些同工酶系统底物之间的体内相互作用程度在很大程度上反映了它们的体外抑制效力。然而，由于药代动力学考虑、代谢产物对同工酶的影响以及几种同工酶共同负责底物代谢的可能性，体外研究受到限制。
